Overview

Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Lipocine Inc.
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate